期刊文献+

羟基喜树碱药物递送系统抗肿瘤研究进展 被引量:4

Research Progress of Hydroxycamptothecine Drug Delivery Systems in Anticancer
下载PDF
导出
摘要 羟基喜树碱(HCPT)作为有效的广谱抗肿瘤药物广泛用于多种肿瘤的治疗,但存在水溶性差、生理pH不稳定性及体内非特异性分布等缺点,限制了其临床应用。近年纳米技术的发展为药物配制和给药过程提供了新的可能方案,各种纳米递送系统可通过表面修饰及配体偶联靶向传递,实现药物高包封率和高细胞摄取效率。因此,基于药物纳米递送系统的出现为提高HCPT制剂的溶解性、渗透性和稳定性,提高药物疗效、降低不良反应发生率、逆转耐药性提供了新思路、新方法。 Hydroxycamptothecin(HCPT),as an effective broad-spectrum anti-tumor drug,is widely used in the treatment of many kinds of tumors.However,its clinical application is limited due to its poor water solubility,physiological pH instability and non-specific distribution in vivo.In recent years,the development of nanotechnology provides new possibilities for drug preparation and delivery.Various nano delivery systems can achieve high drug entrapment efficiency and high cell uptake efficiency through surface modification and ligand coupling.Therefore,the emergence of drug nano delivery system has provided new ideas and methods for improving the solubility,permeability and stability of HCPT preparations,thus improving drug efficacy,reducing the incidence of adverse reactions and reversing drug resistance.
作者 范子琪 徐勤 秦金保 陆信武 FAN Ziqi;XU Qin;QIN Jinbao;LU Xinwu(College of Pharmacy,Guilin Medical University,Guilin 541001,China;Department of Vascular Surgery,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200011,China)
出处 《医学综述》 CAS 2021年第9期1796-1801,共6页 Medical Recapitulate
基金 国家自然科学基金(81660668)。
关键词 肿瘤 羟基喜树碱 药物递送系统 纳米医学 Tumor Hydroxycamptothecin Drug delivery systems Nanomedicine
  • 相关文献

参考文献7

二级参考文献74

  • 1陈军,方芸,张海霞,黄莉莉,钱晓萍,刘宝瑞.雾化吸入羟基喜树碱在兔体内的组织分布[J].药学学报,2004,39(9):747-751. 被引量:12
  • 2吴燕,何文,代文兵,周本宏,宋金春.羟基喜树碱包衣纳米脂质体的处方及制备工艺研究[J].中国药学杂志,2005,40(12):922-925. 被引量:23
  • 3宋金春,黄岭,陈佳丽.羟基喜树碱脂质体的制备及其包封率测定[J].中国医院药学杂志,2007,27(10):1381-1383. 被引量:10
  • 4Urasaki Y, Laco G, Takebayashi Y, et al. Use of camptothecin- resistant mammalian cell lines to evaluate the role of topoi- somerase I in the antiproliferative activity of the indolocarba zole, NB-506, and its topoisomerase I binding site[J]. Cancer Res,2001,61 (2) : 504-508.
  • 5CHENG Yanxiang, CHEN Gantao, HU Min, et al. Has-miR 30a regulates autophagic activity in cervical cancer upon hydroxycamptothecin exposure[J]. Biomedicine ~. Pharmaco therapy, 2015,75 : 67- 74.
  • 6LI Xue-tao, HE Mei li, ZHOU Zhi-yan, et al. The antitumoractivity of PNA modified vinblastine cationic liposomes on Lewis lung tumor cells. In vitro and in vivo evaluation[J]. Int J Pharm,2015,487(1/2):223-233.
  • 7Koide H, Okamoto A, Tsuchida H, et al. One-step encapsula- tion of siRNA between lipid-layers of multi-layer polycation li- posomes by lipoplex freeze-thawing[J]. J Control Release, 2016,228(28) : 1- 8.
  • 8Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential[J]. Drugs, 2002,62(14) : 2 039.
  • 9Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued devel- opment of the camptothecins[J]. Clin Cancer Res, 2002,8 (3):641.
  • 10Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology and interracial inhibition[J]. Chem Rev, 2009, 109 (7) :2 894.

共引文献42

同被引文献60

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部